Form 4: Zoetis Executive Sells Shares Under Pre-Arranged Trading Plan

Zoetis Inc. Executive Vice President Roxanne Lagano sold 652 shares of common stock for $170 per share on June 3, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Roxanne Lagano, Executive Vice President of Zoetis Inc., reported a transaction on June 3, 2025.
• She disposed of 652 shares of Zoetis common stock.
• The shares were sold at a price of $170 per share.
• This transaction was executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following the transaction, Ms. Lagano directly owns 15,129 shares of common stock.
• Additionally, she indirectly holds 814.3248 common stock equivalents in the Zoetis Inc. Savings Plan (401(k)) as of March 31, 2025.

Sentiment

Score: 5

Explanation: Neutral. A routine insider sale under a pre-arranged plan does not typically indicate significant positive or negative sentiment about the company's prospects.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the executive's direct ownership in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends within the animal health sector. Insider sales under 10b5-1 plans are common for executives managing their personal finances.

Comparison to Industry Standards

• As a routine insider transaction report, this document does not contain information suitable for comparison to industry-specific financial benchmarks or competitor performance. It solely details a personal stock transaction by an executive.

Stakeholder Impact

• This transaction is a routine personal financial management activity by an executive and is unlikely to have a direct material impact on shareholders, employees, customers, suppliers, or creditors.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report.

Key Dates

Keywords

Zoetis, ZTS, Form 4, Insider Trading, Stock Sale, Executive Compensation, Rule 10b5-1, Roxanne Lagano, Animal Health